Benitec Biopharma Inc. Income Statement
BNTC|2 years of annual SEC 10-K data (FY2020-FY2021)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Benitec Biopharma Inc. reported $102,000 in revenue and $8M in net loss for FY2021. Revenue decreased 99.2% from FY2020 to FY2021.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.32 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 |
|---|---|---|
| Revenue | $102.0K | $12.2M |
| SG&A Expense | $5.6M | $4.6M |
| R&D Expense | $3.0M | $4.6M |
| Operating Income | -$8.3M | $2.6M |
| Net Income | -$8.3M | $2.6M |
| EPS (Diluted) | -$8.10 | $3.05 |
| Shares Outstanding | 1.1M | 856.8K |
| Operating Margin | -8118.6% | 21.2% |
| Profit Margin | -8111.8% | 21.4% |